MX2015000438A - Manejo de toxicidad para actividad antitumoral de cars. - Google Patents

Manejo de toxicidad para actividad antitumoral de cars.

Info

Publication number
MX2015000438A
MX2015000438A MX2015000438A MX2015000438A MX2015000438A MX 2015000438 A MX2015000438 A MX 2015000438A MX 2015000438 A MX2015000438 A MX 2015000438A MX 2015000438 A MX2015000438 A MX 2015000438A MX 2015000438 A MX2015000438 A MX 2015000438A
Authority
MX
Mexico
Prior art keywords
patient
car
cell
cars
tumor activity
Prior art date
Application number
MX2015000438A
Other languages
English (en)
Spanish (es)
Inventor
Carl H June
Bruce L Levine
Michael D Kalos
Stephan Grupp
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49916566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015000438(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MX2015000438A publication Critical patent/MX2015000438A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
MX2015000438A 2012-07-13 2013-07-12 Manejo de toxicidad para actividad antitumoral de cars. MX2015000438A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261671482P 2012-07-13 2012-07-13
US201361782982P 2013-03-14 2013-03-14
PCT/US2013/050267 WO2014011984A1 (en) 2012-07-13 2013-07-12 Toxicity management for anti-tumor activity of cars

Publications (1)

Publication Number Publication Date
MX2015000438A true MX2015000438A (es) 2016-04-25

Family

ID=49916566

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015000438A MX2015000438A (es) 2012-07-13 2013-07-12 Manejo de toxicidad para actividad antitumoral de cars.
MX2019014761A MX2019014761A (es) 2012-07-13 2015-01-09 Manejo de toxicidad para actividad antitumoral de cars.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019014761A MX2019014761A (es) 2012-07-13 2015-01-09 Manejo de toxicidad para actividad antitumoral de cars.

Country Status (21)

Country Link
US (4) US20150202286A1 (OSRAM)
EP (5) EP2872171B1 (OSRAM)
JP (6) JP6382191B2 (OSRAM)
KR (1) KR102204029B1 (OSRAM)
CN (4) CN111481667A (OSRAM)
AU (2) AU2013289967B2 (OSRAM)
BR (1) BR112015000660A8 (OSRAM)
CA (1) CA2878928C (OSRAM)
DK (4) DK3338794T3 (OSRAM)
EA (1) EA201590210A1 (OSRAM)
ES (4) ES2778701T3 (OSRAM)
FI (2) FI4461308T3 (OSRAM)
HR (2) HRP20230297T1 (OSRAM)
HU (4) HUE048947T2 (OSRAM)
IN (1) IN2014DN11155A (OSRAM)
LT (4) LT3338794T (OSRAM)
MX (2) MX2015000438A (OSRAM)
PL (3) PL4461308T3 (OSRAM)
PT (4) PT4461308T (OSRAM)
SI (2) SI4019041T1 (OSRAM)
WO (1) WO2014011984A1 (OSRAM)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL4461308T3 (pl) 2012-07-13 2025-08-11 The Trustees Of The University Of Pennsylvania Kontrola toksyczności dla aktywności przeciwnowotworowej CAR
US20150320799A1 (en) 2012-12-20 2015-11-12 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
EP3744736A1 (en) 2013-02-20 2020-12-02 Novartis AG Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
KR102313997B1 (ko) 2013-02-20 2021-10-20 노파르티스 아게 인간화 항-EGFRvIII 키메라 항원 수용체를 사용한 암의 치료
EP2970426B1 (en) 2013-03-15 2019-08-28 Michael C. Milone Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
CA3225453A1 (en) 2013-12-19 2015-06-25 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
US10287354B2 (en) 2013-12-20 2019-05-14 Novartis Ag Regulatable chimeric antigen receptor
EP4303229A3 (en) 2014-01-21 2024-04-17 Novartis AG Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
EP4406610A3 (en) 2014-04-07 2024-10-30 Novartis AG Treatment of cancer using anti-cd19 chimeric antigen receptor
EP3134120B1 (en) 2014-04-21 2024-01-24 The Children's Hospital of Philadelphia Compositions and methods for treating cytokine-related disorders
AU2015292744C1 (en) 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
US9777061B2 (en) 2014-07-21 2017-10-03 Novartis Ag Treatment of cancer using a CD33 chimeric antigen receptor
EP3171882A1 (en) 2014-07-21 2017-05-31 Novartis AG Treatment of cancer using a cll-1 chimeric antigen receptor
EP3183268B1 (en) 2014-08-19 2020-02-12 Novartis AG Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
KR20250067191A (ko) 2014-09-17 2025-05-14 노파르티스 아게 입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
CN114107424A (zh) * 2014-10-08 2022-03-01 诺华股份有限公司 预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途
SG11201705293WA (en) 2014-12-29 2017-07-28 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US11459390B2 (en) 2015-01-16 2022-10-04 Novartis Ag Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
PT3253865T (pt) 2015-02-06 2022-10-03 Nat Univ Singapore Métodos para melhorar a eficácia das células imunitárias terapêuticas
WO2016132366A1 (en) 2015-02-18 2016-08-25 Enlivex Therapeutics Ltd. Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US10253086B2 (en) 2015-04-08 2019-04-09 Novartis Ag CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell
ES2948133T3 (es) 2015-04-17 2023-08-31 Novartis Ag Métodos para mejorar la eficacia y expansión de células que expresan un receptor de antígeno quimérico
AU2016250570B2 (en) 2015-04-21 2021-07-01 Enlivex Therapeutics Rdo Ltd Therapeutic pooled blood apoptotic cell preparations and uses thereof
US12128069B2 (en) 2015-04-23 2024-10-29 The Trustees Of The University Of Pennsylvania Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
CN109476722A (zh) 2015-07-21 2019-03-15 诺华股份有限公司 用于改善免疫细胞的功效和扩张的方法
EP3331913A1 (en) 2015-08-07 2018-06-13 Novartis AG Treatment of cancer using chimeric cd3 receptor proteins
CN116334205A (zh) * 2015-09-03 2023-06-27 诺华股份有限公司 预测细胞因子释放综合征的生物标志物
MA44909A (fr) 2015-09-15 2018-07-25 Acerta Pharma Bv Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
AU2016361451B2 (en) 2015-11-27 2024-01-25 Cartherics Pty. Ltd. Genetically modified cells and uses thereof
NZ782855A (en) 2015-12-04 2025-08-29 Novartis Ag Compositions and methods for immunooncology
EP4012415A3 (en) 2015-12-04 2022-12-07 Juno Therapeutics, Inc. Methods and compositions related to toxicity associated with cell therapy
JP7082055B2 (ja) 2015-12-22 2022-06-07 ノバルティス アーゲー 抗癌治療における組み合わせ使用のためのメソテリンキメラ抗原受容体（ｃａｒ）およびｐｄ－ｌ１阻害剤に対する抗体
JP6853514B2 (ja) * 2015-12-27 2021-03-31 国立大学法人東海国立大学機構 炎症性サイトカインの産生が抑制されるキメラ抗原受容体遺伝子改変リンパ球
CN109069539A (zh) * 2016-02-18 2018-12-21 恩立夫克治疗有限责任公司 用于癌症治疗的联合免疫疗法和细胞因子控制疗法
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
JP7048571B2 (ja) 2016-03-22 2022-04-05 シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） 毒性を予防または改善するための早期介入法
EP3432924A1 (en) 2016-03-23 2019-01-30 Novartis AG Cell secreted minibodies and uses thereof
EP3439675A4 (en) 2016-04-08 2019-12-18 Purdue Research Foundation METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY
CN109414512A (zh) 2016-04-22 2019-03-01 科济生物医药（上海）有限公司 用于细胞免疫疗法的组合物和方法
WO2017189959A1 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
MA45341A (fr) * 2016-06-06 2019-04-10 Hutchinson Fred Cancer Res Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive
CN109563507B (zh) * 2016-07-08 2024-03-05 埃克苏马生物技术公司 用于转导淋巴细胞及调节其活性的方法及组合物
SG11201900344YA (en) 2016-07-15 2019-02-27 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
CA3032581A1 (en) * 2016-08-01 2018-02-08 Novartis Ag Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
CN117866991A (zh) 2016-10-07 2024-04-12 诺华股份有限公司 用于治疗癌症的嵌合抗原受体
CN106636090B (zh) * 2016-10-11 2019-08-09 上海优卡迪生物医药科技有限公司 人源白细胞介素6的siRNA、重组表达CAR-T载体及其构建方法和应用
RU2019120398A (ru) * 2016-12-03 2021-01-12 Джуно Терапьютикс, Инк. Способы определения дозировки cart-клеток
WO2018102785A2 (en) 2016-12-03 2018-06-07 Juno Therapeutics, Inc. Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors
CN108148863B (zh) * 2016-12-05 2019-12-17 上海优卡迪生物医药科技有限公司 一种封闭il6r的用于缓解crs的car-t转基因载体及其构建方法和应用
CN108250301A (zh) * 2016-12-29 2018-07-06 天津天锐生物科技有限公司 一种多靶点嵌合抗原受体
EP3574005B1 (en) 2017-01-26 2021-12-15 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
EP3579870A4 (en) 2017-02-07 2020-12-30 Seattle Children's Hospital (DBA Seattle Children's Research Institute) PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS
BR112019017767A2 (pt) 2017-02-27 2020-04-07 Juno Therapeutics Inc composições, artigos de fabricação e métodos relacionados à dosagem em terapia celular
EP3589295B1 (en) 2017-02-28 2024-09-11 Endocyte, Inc. Compositions and methods for car t cell therapy
EP3601561A2 (en) 2017-03-22 2020-02-05 Novartis AG Compositions and methods for immunooncology
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
US20200333329A1 (en) * 2017-05-01 2020-10-22 H. Lee Moffitt Cancer Center And Research Institute, Inc. Targeted cytokine blockades for car-t therapy
CN118662614A (zh) 2017-06-02 2024-09-20 朱诺治疗学股份有限公司 使用过继细胞疗法治疗的制品和方法
CA3064893A1 (en) * 2017-06-08 2018-12-13 Enlivex Therapeutics Ltd. Therapeutic apoptotic cells for cancer therapy
AU2018313939A1 (en) 2017-08-10 2020-02-06 National University Of Singapore T cell receptor-deficient chimeric antigen receptor T-cells and methods of use thereof
US11673962B2 (en) 2017-10-02 2023-06-13 Humanigen, Inc. Method of increasing the efficacy of CAR-T immunotherapy using lenzilumab
WO2019079564A1 (en) * 2017-10-18 2019-04-25 Kite Pharma, Inc. METHODS OF DELIVERY OF CHIMERIC ANTIGEN RECEPTOR IMMUNOTHERAPY
CA3079407A1 (en) 2017-10-18 2019-04-25 Novartis Ag Compositions and methods for selective protein degradation
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
PT3704230T (pt) 2017-11-01 2024-11-19 Juno Therapeutics Inc Processo para gerar composições terapêuticas de células modificadas
US11564946B2 (en) 2017-11-01 2023-01-31 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
CA3089319A1 (en) 2018-01-22 2019-07-25 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for car t cells
US12312416B2 (en) 2018-02-06 2025-05-27 Seattle Children's Hospital Fluorescein-specific cars exhibiting optimal t cell function against FL-PLE labelled tumors
CN108300807A (zh) * 2018-02-07 2018-07-20 安徽古生物科技有限公司 针对第四代嵌合抗原受体car载体pcr鉴定的方法
JP7568224B2 (ja) 2018-02-23 2024-10-16 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための配列決定法
EP3762012A1 (en) * 2018-03-09 2021-01-13 Ospedale San Raffaele S.r.l. Il-1 antagonist and toxicity induced by cell therapy
CA3093827A1 (en) * 2018-03-14 2019-09-19 Celledit Llc Modification of immune cells for reducing toxicity and uses thereof in adoptive cell therapy
BR112020018620A2 (pt) 2018-03-15 2020-12-29 KSQ Therapeutics, Inc. Composições de regulação gênica e métodos para imunoterapia aprimorada
US10869888B2 (en) 2018-04-17 2020-12-22 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
US20210396739A1 (en) 2018-05-01 2021-12-23 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
US12129485B2 (en) 2018-05-23 2024-10-29 National University Of Singapore Blockade of CD2 surface expression and expression of chimeric antigen receptors for immunotherapy of T-cell malignancies
WO2019227003A1 (en) 2018-05-25 2019-11-28 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
CN112533942A (zh) 2018-06-01 2021-03-19 华盛顿大学 嵌合抗原受体细胞疗法中细胞因子释放综合征的抑制
AU2019277660A1 (en) * 2018-06-01 2021-01-21 Mayo Foundation For Medical Education And Research Materials and methods for treating cancer
US11608382B2 (en) 2018-06-13 2023-03-21 Novartis Ag BCMA chimeric antigen receptors and uses thereof
CN108949759B (zh) * 2018-07-23 2021-06-01 合肥一兮生物科技有限公司 敲减人IL-15的siRNA、CD19 CAR表达载体、CAR-T细胞及构建方法和应用
JP2021532116A (ja) 2018-07-23 2021-11-25 マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. 同種異系の細胞療法における抗−ｃｄ５抗体薬物コンジュゲート（ａｄｃ）の使用
KR102842215B1 (ko) * 2018-08-10 2025-08-05 주식회사 유틸렉스 Hla-dr에 결합하는 키메라 항원 수용체 및 car-t 세포
US12240915B2 (en) 2018-08-30 2025-03-04 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
CA3111804A1 (en) * 2018-09-10 2020-03-19 Humanigen, Inc. Methods of treating immunotherapy-related toxicity using a gm-csf antagonist
MX2021004993A (es) * 2018-10-31 2021-06-15 Humanigen Inc Materiales y metodos para tratar cancer.
EP3880238A1 (en) * 2018-11-16 2021-09-22 Juno Therapeutics, Inc. Methods of dosing engineered t cells for the treatment of b cell malignancies
US10918667B2 (en) 2018-11-20 2021-02-16 Innovative Cellular Therapeutics CO., LTD. Modified cell expressing therapeutic agent and uses thereof
CN120005921A (zh) 2018-12-12 2025-05-16 凯德药业股份有限公司 嵌合抗原和t细胞受体及使用的方法
US12491247B2 (en) 2019-01-07 2025-12-09 Celluris Llc Bispecific in tandem receptor car and method for modulating the tumoral microenvironment
CN112430579A (zh) * 2019-08-26 2021-03-02 深圳宾德生物技术有限公司 靶向Her2并干扰IL-6表达的嵌合抗原受体T细胞及其制备方法和应用
JP7714545B2 (ja) 2019-11-26 2025-07-29 ノバルティス アーゲー キメラ抗原受容体及びその使用
KR20220104217A (ko) 2019-11-26 2022-07-26 노파르티스 아게 Cd19 및 cd22 키메라 항원 수용체 및 이의 용도
US12076343B2 (en) 2020-02-19 2024-09-03 Innovative Cellular Therapeutics Holdings, Ltd. Engineered safety in cell therapy
TW202144400A (zh) * 2020-02-20 2021-12-01 美商凱特製藥公司 嵌合抗原受體t細胞療法
US12043654B2 (en) 2020-06-02 2024-07-23 Innovative Cellular Therapeutics Holdings, Ltd. Anti-GCC antibody and CAR thereof for treating digestive system cancer
EP3988116A1 (en) * 2020-10-23 2022-04-27 Consejo Superior De Investigaciones Científicas (CSIC) Methods and compositions for the treatment of hematologic malignancies
TW202237827A (zh) 2020-12-03 2022-10-01 美商世紀治療股份有限公司 經基因工程改造之細胞及其用途
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
CA3202218A1 (en) 2020-12-18 2022-06-23 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
JP2024506831A (ja) 2021-01-28 2024-02-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッド サイトカイン放出症候群を治療するための組成物及び方法
EP4298120A1 (en) 2021-02-25 2024-01-03 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
WO2023004055A1 (en) * 2021-07-21 2023-01-26 The Cleveland Clinic Foundation Metabolic and inflammatory markers for car-t cell therapy
IL312250A (en) * 2021-10-27 2024-06-01 Univ Rush Medical Center Methods for treating the effects of cytokine storms
WO2023159001A1 (en) * 2022-02-15 2023-08-24 Kite Pharma, Inc. Predicting adverse events from immunotherapy
EP4604976A1 (en) * 2022-10-20 2025-08-27 Microcrispr Pvt Ltd. Attenuation of cytokine release syndrome in immunotherapy

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
ATE195022T1 (de) 1987-04-27 2000-08-15 Unilever Nv Spezifische bindungstestverfahren
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
US6267722B1 (en) 1998-02-03 2001-07-31 Adeza Biomedical Corporation Point of care diagnostic systems
US6656745B1 (en) 2000-06-02 2003-12-02 Francis X. Cole Devices and methods for a multi-level, semi-quantitative immunodiffusion assay
AU2008207646A1 (en) * 2001-10-04 2008-09-25 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
EP1670787B1 (en) * 2003-09-11 2012-05-30 iTherX Pharma, Inc. Cytokine inhibitors
AU2004274909B8 (en) * 2003-09-15 2010-06-10 Oklahoma Medical Research Foundation Method of using cytokine assays to diagnose, treat, and evaluate inflammatory and autoimmune diseases
US7189522B2 (en) 2005-03-11 2007-03-13 Chembio Diagnostic Systems, Inc. Dual path immunoassay device
US7935340B2 (en) 2007-05-21 2011-05-03 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
WO2008157282A1 (en) * 2007-06-18 2008-12-24 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
US9452227B2 (en) * 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
WO2010065072A1 (en) 2008-11-25 2010-06-10 Alden Biopharmaceuticals, Inc. Antagonists of il-6 to raise albumin and/or lower crp
WO2010075249A2 (en) * 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
WO2011066378A2 (en) 2009-11-24 2011-06-03 Alder Biopharmaceuticals, Inc. Antagonists of il-6 to prevent or treat thrombosis
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2013033626A2 (en) 2011-08-31 2013-03-07 Trustees Of Dartmouth College Nkp30 receptor targeted therapeutics
EA026436B9 (ru) 2012-07-04 2017-07-31 Ин Энд Тек С.Р.Л. Шарнирная петля для вращательного движения двери, в частности армированной двери
PL4461308T3 (pl) 2012-07-13 2025-08-11 The Trustees Of The University Of Pennsylvania Kontrola toksyczności dla aktywności przeciwnowotworowej CAR

Also Published As

Publication number Publication date
EP3721901A1 (en) 2020-10-14
EP3338794A1 (en) 2018-06-27
JP7034125B2 (ja) 2022-03-11
HUE053556T2 (hu) 2021-07-28
JP2019182874A (ja) 2019-10-24
DK4019041T3 (da) 2023-04-03
ES2859522T3 (es) 2021-10-04
PT3338794T (pt) 2020-04-24
DK3338794T3 (da) 2020-05-04
JP2019006782A (ja) 2019-01-17
KR102204029B1 (ko) 2021-01-19
HRP20230297T1 (hr) 2023-05-12
LT4019041T (lt) 2023-04-11
JP2018150320A (ja) 2018-09-27
JP2025013518A (ja) 2025-01-24
PL4461308T3 (pl) 2025-08-11
SI4461308T1 (sl) 2025-09-30
HK1253365A1 (en) 2019-06-14
AU2018203924A1 (en) 2018-06-21
CN104427997A (zh) 2015-03-18
DK4461308T3 (da) 2025-06-23
MX2019014761A (es) 2020-02-12
CN104427997B (zh) 2020-12-11
JP6563554B2 (ja) 2019-08-21
JP2015522081A (ja) 2015-08-03
CN111467494B (zh) 2023-05-02
AU2018203924B2 (en) 2020-04-16
ES2778701T3 (es) 2020-08-11
HUE072215T2 (hu) 2025-10-28
ES2941370T3 (es) 2023-05-22
EP4461308B1 (en) 2025-04-16
SI4019041T1 (sl) 2023-04-28
AU2013289967B2 (en) 2018-03-29
US11273219B2 (en) 2022-03-15
JP6382191B2 (ja) 2018-08-29
PT4019041T (pt) 2023-03-29
ES3032321T3 (en) 2025-07-17
JP2022066304A (ja) 2022-04-28
HUE061555T2 (hu) 2023-07-28
CN111481667A (zh) 2020-08-04
EA201590210A1 (ru) 2015-08-31
HRP20250822T1 (hr) 2025-09-26
LT4461308T (lt) 2025-06-10
US20180256712A1 (en) 2018-09-13
US10603378B2 (en) 2020-03-31
US20150202286A1 (en) 2015-07-23
PT2872171T (pt) 2021-03-31
AU2013289967A1 (en) 2015-01-22
CN108379586A (zh) 2018-08-10
EP3338794B1 (en) 2020-02-26
CN111467494A (zh) 2020-07-31
PL4019041T3 (pl) 2023-05-08
WO2014011984A1 (en) 2014-01-16
EP4019041B1 (en) 2022-12-28
IN2014DN11155A (OSRAM) 2015-10-02
EP2872171A4 (en) 2016-02-10
CA2878928C (en) 2023-03-14
EP2872171A1 (en) 2015-05-20
LT3338794T (lt) 2020-05-25
EP4461308A2 (en) 2024-11-13
BR112015000660A2 (pt) 2014-01-16
EP4019041A1 (en) 2022-06-29
JP7682820B2 (ja) 2025-05-26
US20180243411A1 (en) 2018-08-30
CA2878928A1 (en) 2014-01-16
KR20150042784A (ko) 2015-04-21
BR112015000660A8 (pt) 2019-07-16
EP4461308A3 (en) 2024-12-11
EP2872171B1 (en) 2021-01-06
FI4019041T3 (fi) 2023-04-03
HUE048947T2 (hu) 2020-09-28
DK2872171T3 (da) 2021-03-08
LT2872171T (lt) 2021-04-26
PT4461308T (pt) 2025-07-11
FI4461308T3 (fi) 2025-07-09
US20230013642A1 (en) 2023-01-19
PL2872171T3 (pl) 2021-07-12

Similar Documents

Publication Publication Date Title
MX2015000438A (es) Manejo de toxicidad para actividad antitumoral de cars.
MX2018009820A (es) Uso de cart19 para eliminar celulas b normales para inducir tolerancia.
MX2014010181A (es) Uso de cars a base de icos para incrementar la actividad antitumor y persistencia a car.
MX377858B (es) Combinación de moleculas inhibidoras de semaforina-4d con agentes inmunomoduladores y usos de los mismos.
CL2015000699A1 (es) Métodos para tratamiento de cáncer.
EA201790195A1 (ru) Способы лечения рака с применением ингибиторов tigit и противораковых агентов
MX2016006177A (es) Método para diseñar células t resistentes a fármacos de quimioterapia para inmunoterapia.
CO7160093A2 (es) Anticuerpos anti-egfr y usos de los mismos
NI201500131A (es) Virus de la enfermedad de newcastle y usos de los mismos
MX2016007351A (es) Terapia de combinacion para tratar cancer.
HK1211832A1 (zh) 用於癌症療法的抗高血壓藥物的新穎配方及用法
MX373925B (es) Tratamiento del cancer con inhibidores de tor cinasa.
NZ700759A (en) Combination therapy for treating cancer
MX2016000271A (es) Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r.
NI201300051A (es) Uso de células t de receptor modificado antígeno quiméricas para tratar el cáncer.
IN2014DN09098A (OSRAM)
MX2015011753A (es) Metodos para tratar cancer de vegija.
BR112014008294A2 (pt) anticorpo anti c-met e usos do mesmo
MX2016004285A (es) Tratamiento de tumor por combinacion con minicelulas dirigidas a ligando, biespecificas, cargadas con farmacos e interferon-gamma.
MX369609B (es) Una composición para usarse en el tratamiento de cáncer deficiente en nmt2.
MX2015014599A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer.
MX359210B (es) Composición de combinación de pac-1 y tamoxifeno.
MX359209B (es) Terapia de combinacion de procaspasa para gliobastoma.
MX2015006096A (es) Leucocitos como celulas de administracion para imagen y terapia de enfermedad.
NZ704554A (en) Combination therapy of a smac mimetic and gm-csf

Legal Events

Date Code Title Description
FG Grant or registration